|
30 Sep 2022 |
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
|
|
30 Sep 2022 |
Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical trial of KBA1412 in Patients with Advanced Solid Tumors
|
|
29 Sep 2022 |
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
|
|
29 Sep 2022 |
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
|
|
28 Sep 2022 |
Ichnos Sciences announces initiation of first-in-human study for ISB 1442
|
|
28 Sep 2022 |
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
|
|
28 Sep 2022 |
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
|
|
28 Sep 2022 |
Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody
|
|
28 Sep 2022 |
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma® (bevacizumab-adcd) for the Treatment of Six Types of Cancer
|
|
28 Sep 2022 |
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
|
|
28 Sep 2022 |
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
|
|
28 Sep 2022 |
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
|
|
28 Sep 2022 |
Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
|
|
28 Sep 2022 |
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
|
|
28 Sep 2022 |
Lecanemab confirmatory phase 3 Clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer's disease
|
|
27 Sep 2022 |
First Patient Enrolled in ProstACT TARGET Study
|
|
27 Sep 2022 |
Angel Pharmaceuticals Announces Approval of IND Application for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
|
|
27 Sep 2022 |
Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke
|
|
27 Sep 2022 |
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
|
|
23 Sep 2022 |
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
|
|
23 Sep 2022 |
Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis
|
|
22 Sep 2022 |
Almirall announces the initiation of a phase I study of anti-IL-1RAP first-in-class monoclonal antibody for autoimmune dermatological diseases
|
|
21 Sep 2022 |
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
|
|
21 Sep 2022 |
Tezspire approved in the EU for the treatment of severe asthma
|
|
20 Sep 2022 |
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
|
